Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 26;21(2):607–614. doi: 10.3892/mmr.2019.10851

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Li et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 5. — Disruption of the calcineurin/NFAT4 pathway attenuates MV-induced pathological changes, edema and MPO activity in the lungs of rats. (A and B) Pretreatment with CsA inhibited MV-induced pathological changes. Pretreatment with CsA decreased (C) the wet/dry weight ratios and (D) the protein levels of BALF. (E) Pretreatment with CsA inhibited the MV-induced MPO activity. The data are presented as the means ± SD (n=8). *P<0.05 compared with the Control group; ^#P<0.05 compared with the HV group. MV, mechanical ventilation; CsA, calcineurin inhibitor; LV, ventilated with a low tidal volume; HV, ventilated with a high tidal volume.